Dymista (Azelastine/Fluticasone) Patent Expiration, LOE Window & CMS Spending

Dymista (Azelastine/Fluticasone) by Viatris: FDA Orange Book LOE 2026-08-24, 3 AB generics, $4.2M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorViatris
FDA Application & PathwayN202236 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2026-08-24
Orange Book Patents (*PED Extensions)2 patents (1 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$4.2M
2024 Medicare Part D Spend$604K
2024 Medicaid Spend$3.6M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Viatris across sibling Meru public-data platforms.